Shmuel Hess Biography and Net Worth

COO of MediWound

Dr. Shmulik Hess is the Chief Operating Officer & Chief Commercial Officer at MediWound. He brings over two decades of expertise in drug development and commercial operations within the healthcare sector. Before joining MediWound, he served as CEO at Tabby Therapeutics, Enlivex Therapeutics (Nasdaq: ENLV), and Valin Technologies. He also held a global operations executive role at SciGen Ltd. (acquired by VBI Vaccines).

Dr. Hess has a strong background in operational strategy, sales, and commercial leadership in the global biopharma industry. He is the inventor of multiple patents and the author of numerous peer-reviewed scientific publications.

Dr. Hess holds a Ph.D. in Pharmaceutical Science from the Hebrew University of Jerusalem and was a research fellow at the Harvard-MIT Health Sciences and Technology (HST) program.

How do I contact Shmuel Hess?: The corporate mailing address for Hess and other MediWound executives is 42 HAYARKON STREET, YAVNE L3, 8122745. MediWound can also be reached via phone at 972779714100 and via email at [email protected]. Learn More on Shmuel Hess' contact information.
Has Shmuel Hess been buying or selling shares of MediWound?: During the past quarter, Shmuel Hess has sold $75,382.36 of MediWound stock. Most recently, Shmuel Hess sold 3,958 shares of the business's stock in a transaction on Thursday, August 27th. The shares were sold at an average price of $12.92, for a transaction totalling $51,137.36. Learn More on Shmuel Hess' trading history.
Are insiders buying or selling shares of MediWound?: During the last twelve months, MediWound insiders bought shares 2 times. They purchased a total of 3,687 shares worth more than $52,056.57. During the last twelve months, insiders at the biopharmaceutical company sold shares 2 times. They sold a total of 5,823 shares worth more than $75,382.36. The most recent insider tranaction occured on August, 27th when COO Shmuel Hess sold 3,958 shares worth more than $51,137.36. Insiders at MediWound own 9.2% of the company. Learn More about insider trades at MediWound.
Information on this page was last updated on 8/27/2026.

Shmuel Hess Insider Trading History at MediWound

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
8/27/2026	Sell	3,958	$12.92	$51,137.36
8/26/2026	Sell	1,865	$13.00	$24,245.00

Shmuel Hess Buying and Selling Activity at MediWound

MediWound Company Overview

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; and MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.

Today's Range

Now: $12.82

$12.70

$12.98

50 Day Range

MA: $14.10

$12.61

$15.19

2 Week Range

Now: $12.82

$12.52

$20.30

Volume

8,637 shs

Average Volume

92,814 shs

Market Capitalization

$164.67 million

P/E Ratio

N/A

Dividend Yield